Breast Cancer With Low Expression of HER2
Conditions
Keywords
ARX788, Breast cancer, Low expression of HER2
Brief summary
A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.
Detailed description
A single arm, phase 2 study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2. Subjects should received ≥2 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received ≥2-line endocrine therapy ± targeted therapy (including neoadjuvant/adjuvant therapy). HER2 low expression is defined as HER2 IHC 1+ or HER2 IHC 2+ and FISH negative. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
Interventions
DRUGARX788
1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Willing and able to understand and sign an informed consent inform; * Age ≥18 years, and ≤75 years, male or female; * Diagnosed as HR arbitrary/HER2 low expression unresectable and/or metastatic breast cancer. HER2 low expression is defined as HER2 IHC 1+ (FISH negative or FISH not done) or HER2 IHC 2+ and FISH negative; * Received ≥2 lines of systemic chemotherapy regimens for recurrent or metastatic disease, and for HR positive subjects, also need to have received ≥2-line endocrine therapy ± targeted therapy (including neoadjuvant/adjuvant therapy); * Never had a HER2 positive result (IHC 3+ or FISH+) in previous pathological examinations; * Have archived or fresh tumor tissue samples for HER2 status confirmation; * According to the RECIST 1.1 standard, there is at least one measurable lesion; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1; LVEF≥50%; * Adequate organ functions; * Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1; * Life expectancy ≥ 3 months.
Exclusion criteria
* History of allergic reactions to any component of ARX788, or with a history of protein drug allergy, a history of specific allergies (asthma, rheumatism, eczematous dermatitis), or a history of other severe allergic reactions, who are unsuitable for ARX788 treatment as per the investigator's judgments; * Previous treatment with T-DM1 or other HER2-ADC drugs; * Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured); * Have primary central nervous system (CNS) tumors or CNS metastases; * Prior history of interstitial pulmonary disease requiring hormone therapy, drug-induced interstitial pulmonary disease, radiation pneumonia, or current clinically active interstitial pulmonary disease; * Suffering from keratitis, corneal diseases, retinal diseases or active eye infections that require intervention; * Unwilling or unable to stop wearing contact lenses for the duration of the study; * Cardiac insufficiency; * Uncontrolled hypertension; * Suffering severe or uncontrolled systemic diseases; * Had chemotherapy, radiotherapy, or immunotherapy within 4 weeks before the first dose; * Had breast cancer endocrine therapy within 2 weeks before the first dose; * Had palliative radiotherapy for bone metastasis within 2 weeks before the first dose; * Any uncontrolled infection, or other conditions that may limit trial compliance or interfere with evaluation; * Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or syphilis; * Plan to receive major surgical treatment within 2 weeks before first dose or during the trial period, or have suffered severe traumatic injury; * Pregnancy or lactation; * Unwilling or unable to use acceptable methods for contraception during the entire treatment period of this trial and within 8 months after the last dose; * Participated in other clinical trials and used other experimental drugs within 4 weeks before the first dose; * Any mental or cognitive impairment may limit their understanding and implementation of the informed consent form; * Not suitable for participating in this trial, such as poor compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate (ORR) | 2 years | ORR is defined as the percentage of subjects who have achieved complete response and partial response according RECIST 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 2 years | PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy |
| Overall survival (OS) | 2 years | Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive |
| Disease control rate (DCR) | 2 years | Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study |
| Duration of relief (DOR) | 2 years | DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death |
Countries
China
Contacts
Primary ContactTing Li
Outcome results
None listed